Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;21(9):620–624. doi: 10.1002/clc.4960210904

Potential cardiovascular applications of glutamate, aspartate, and other amino acids

Michael Arsenian 1,✉
PMCID: PMC6655781  PMID: 9755377

Abstract

Cardioplegic solutions rich in the hydrophilic, basic amino acids, glutamate and aspartate, have enhanced myocardial preservation and left ventricular function. This has been demonstrated in assorted animal preparations involving ischemia with and without reperfusion. Published clinical data, though limited, strongly support the contention that these amino acids have myocardial protective properties. Several biochemical mechanisms exist by which certain amino acids may attenuate ischemic or reperfusion injury. Glutamate and aspartate may become preferred myocardial fuels in the setting of ischemia. They may also reduce myocardial ammonia production and reduce cytoplasmic lactate levels, thereby deinhibiting glycolysis. Some amino acids may become substrate for the citric acid cycle. Glutamate and aspartate also move reducing equivalents from cytoplasm to mitochondria where they are necessary for oxidative phosphorylation and energy generation. A rationale exists for the use of an amino acid‐rich cardioplegia‐like solution in myocardial infarction. These solutions are safe and inexpensive.

Keywords: glutamate, aspartate, cardioplegia

Full Text

The Full Text of this article is available as a PDF (548.7 KB).

References

  • 1. Opie LH: Metabolism of the heart in health and disease. Am Heart J 1968; 76: 685–698 [DOI] [PubMed] [Google Scholar]
  • 2. Pozefsky T, Felig P, Tobin JD, Soeldner JS, Cahill GF: Amino acid balance across tissues of the forearm in postabsorptive man. J Clin Invest 1969; 48: 2273–2282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Svedjeholm R, Ekroth R, Joachimsson P, Ronquist G, Svensson S, Tyden H: Myocardial uptake of amino acids and other substrates in relation to myocardial oxygen consumption four hours after cardiac operations. J Thorac Cardiovasc Surg 1991; 101: 688–694 [PubMed] [Google Scholar]
  • 4. Taegtmeyer H, Peterson MH, Ragavan VV, Ferguson AG, Lesch M: De novo alanine synthesis in isolated oxygen‐deprived rabbit myocardium. J Biol Chem 1977; 252: 5010–5018 [PubMed] [Google Scholar]
  • 5. Gailis L, Benmouyal E: Endogenous alanine, glutamate, aspartate, and glutamine in perfused guinea‐pig heart. Effect of substrates and cardioactive agents. Can J Biochem 1973; 51: 11–20 [DOI] [PubMed] [Google Scholar]
  • 6. Veitch K, Hombroeckx A, Caucheteux D, Pouleur H, Hue L: Global ischaemia induces a biphasic response of the mitochondrial respiratory chain. Biochem J 1992; 281: 709–715 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Berkowitz S, Perrile P, Lesch M: Anaerobic amino acid metabolism as a potential energy source in mammalian hearts. Clin Res 1978; 26: 291A [Google Scholar]
  • 8. Mudge GH, Mills RM, Taegtmeyer H, Gorlin R, Lesch M: Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Sci Invest 1976; 58: 1185–1192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Thomassen AR, Nielsen TT, Bagger JP, Henningsen P: Myocardial exchange of glutamate, alanine, and citrate in controls and patients with coronary artery disease. Clin Sci 1983; 64: 33–40 [DOI] [PubMed] [Google Scholar]
  • 10. Knapp WH, Helus F, Ostertag H, Tillman H, Kubler W: Uptake and turnover of L‐(13N)‐glutamate in the normal human heart and in patients with coronary artery disease. Eur J Nucl Med 1982; 7: 211–215 [DOI] [PubMed] [Google Scholar]
  • 11. Taegtmeyer H: Metabolic responses to cardiac hypoxia: Increased production of succinate by rabbit papillary muscles. Circ Res 1978; 43: 808–815 [DOI] [PubMed] [Google Scholar]
  • 12. Sanborn T, Gavin W, Berkowitz S, Perille T, Lesch M: Augmented conversion of aspartate and glutamate to succinate during anoxia in rabbit heart. Am J Physiol 1979; 237: H535–H541 [DOI] [PubMed] [Google Scholar]
  • 13. Owen TG, Hochachka PW: Purification and properties of dolphin muscle aspartate and alanine transaminases and their possible role in the energy metabolism of diving mammals. Biochem J 1974; 143: 541–553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Hochachka PW, Storey KB: Metabolic consequences of diving in animals and man. Science 1975; 187: 613–621 [DOI] [PubMed] [Google Scholar]
  • 15. Hochachka PW, Owen TG, Allen JF, Whitlow EC: Multiple end products of anaerobiosis in diving vertebrates. Comp Biochem Physiol 1975; 50B: 17–22 [DOI] [PubMed] [Google Scholar]
  • 16. Kirkendol PL, Pearson JE. Robie NW: The cardiac and vascular effects of sodium glutamate. Clin Exp Pharm Physiol 1980; 7: 617–625 [DOI] [PubMed] [Google Scholar]
  • 17. Thomassen A, Nielsen TT. Bagger JP, Henningsen P: Effects of intravenous glutamate on substrate availability and utilization across the human heart and leg. Metabolism 1991; 40: 378–384 [DOI] [PubMed] [Google Scholar]
  • 18. Davis EJ, Bremmer J: Studies with isolated surviving rat hearts. Interdependence of free amino acids and citric acid‐cycle intermediates. Eur J Biochem 1973; 38: 86–97 [DOI] [PubMed] [Google Scholar]
  • 19. Pisarenko OI, Lepilin MG. Ivanov VE: Cardiac metabolism and performance during L‐glutamic acid infusion in postoperative cardiac failure. Clin Sci 1986; 70: 7–12 [DOI] [PubMed] [Google Scholar]
  • 20. Watanabe T, Yamakazi A, Aoyama S: Significance of myocardial ammonia metabolism in the failing heart. Israel J Med Sci 1969; 5: 496–500 [PubMed] [Google Scholar]
  • 21. Burns AH, Reddy WJ: Amino acid stimulation of oxygen and substrate utilization by cardiac myocytes. Am J Physiol 1978; 235: E461–E466 [DOI] [PubMed] [Google Scholar]
  • 22. Rau EE, Shine KI, Gervais A, Douglas AM, Amos EC: Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion. Am J Physiol 1979; 236: H873–H879 [DOI] [PubMed] [Google Scholar]
  • 23. Cairns C, Ferroggiaro A, Walther J, Harken A, Banerjee A: Postishemic administration of succinate reverses the impairment of oxidative phosphorylation after cardiac ischemia and reperfusion injury. Circulation 1996; 94: I–414 [PubMed] [Google Scholar]
  • 24. Taegtmeyer H, Ferguson AG, Lesch M: Protein degradation and amino acid metabolism in autolyzing rabbit myocardium. Exp Mol Pathol 1977; 26: 52–62 [DOI] [PubMed] [Google Scholar]
  • 25. Penney DG, Cascarano J: Anaerobic rat heart: Effects of glucose and tricarboxylic acid cycle metabolites on metabolism and physiological performance. Biochem J 1970; 118: 221–227 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Pisarenko OI, Solomatina ES, Studneva JM, Ivanov VE, Kapelko VI. Smirnov VN: Protective effect of glutamic acid on cardiac function and metabolism during cardioplegia and reperfusion. Basic Res Cardiol 1983; 78: 534–543 [DOI] [PubMed] [Google Scholar]
  • 27. Singh J, Garg KN, Garg D, Chugh K, Lal H: Effect of aspartate and glutamate on experimental myocardial infarction in rats. Ind J Exp Biol 1989; 27: 621–624 [PubMed] [Google Scholar]
  • 28. Bittl JA, Shine KI: Protection of ischemic rabbit myocardium by glutamic acid. Am J Physiol 1983; 245: H406–H412 [DOI] [PubMed] [Google Scholar]
  • 29. Julia P, Young HH, Buckberg GD, Kofsky ER, Bugyi HI: Studies of myocardial protection in the immature heart. J Thorac Cardiovasc Surg 1991; 101: 23–32 [PubMed] [Google Scholar]
  • 30. Lazar HL, Buckberg GD. Manganaro AJ, Becker H, Maloney JV: Reversal of ischemic damage with amino acid substrate enhancement during reperfusion. Surgery 1980; 88: 702–709 [PubMed] [Google Scholar]
  • 31. Lazar HL, Buckberg GD, Manganaro AM, Becker H: Myocardial energy replenishment and reversal of ischemic damage by substrate enhancement of secondary blood cardioplegia with amino acids during reperfusion. J Thorac Cardiovasc Surg 1980; 80: 350–359 [PubMed] [Google Scholar]
  • 32. Rosenkranz E, Okamoto F, Buckberg G, Vinten‐Johansen J, Robertson J, Bugyi H: Safety of prolonged aortic clamping with blood cardioplegia. II. Glutamate enrichment in energy‐depleted hearts. J Thorac Cardiovasc Surg 1984; 88: 402–410 [PubMed] [Google Scholar]
  • 33. Rosenkranz ER, Okamoto F, Buckberg GD, Robertson JM, Vinten‐Johansen J, Bugyi HI: Safety of prolonged aortic clamping with blood cardioplegia. III. Aspartate enrichment of glutamate‐blood cardioplegia in energy‐depleted hearts after ischemic and reperfusion injury. J Thorac Cardiovasc Surg 1986; 91: 428–435 [PubMed] [Google Scholar]
  • 34. Engleman RM, Rosou JA, Flack JE, Iyengar J. Kimura Y, Das DK: Reduction of infarct size by systemic amino acid supplementation during reperfusion. J Thorac Cardiovasc Surg 1991; 101: 855–859 [PubMed] [Google Scholar]
  • 35. Beyersdorf F, Acar C, Buckberg GDI: Studies on prolonged acute regional ischemia. V. Metabolic support of remote myocardium during left ventricular power failure. J Thorac Cardiovasc Surg 1989; 98: 567–579 [PubMed] [Google Scholar]
  • 36. Gharagozloo F, Melendez F, Hein R: The effect of amino acid L‐glutamate on the extended preservation ex vivo of the heart for transplantation. Circulation 1987; 6 (suppl V): 65–70 [PubMed] [Google Scholar]
  • 37. Kjellman U, Bjork K, Ekroth R: Alpha‐ketoglutarate for myocardial protection in heart surgery. Lancet 1995; 345: 552–553 [DOI] [PubMed] [Google Scholar]
  • 38. Robertson J, Vinten‐Johansen J, Buckberg G. Rosenkranz E, Moloney J: Safety of prolonged aortic clamping with blood cardioplegia. I. Glutamate enrichment in normal hearts. J Thorac Cardiovasc Surg 1984; 88: 395–401 [PubMed] [Google Scholar]
  • 39. Thomassen A, Botker HE, Nielsen TT. Thygesen K, Henningsen P: Effects of glutamate on exercise tolerance and circulation substrate levels in stable angina pectoris. Am J Cardiol 1990; 65: 173–178 [DOI] [PubMed] [Google Scholar]
  • 40. Thomassen A, Nielsen TT, Bagger JP, Pedersen AK, Henningsen P: Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X. Am J Cardiol 1991; 68: 291–295 [DOI] [PubMed] [Google Scholar]
  • 41. Svedjeholm R, Huljebrant I, Hakanson E. Vanhanen I: Glutamate and high‐dose glucose‐insulin‐potassium in the treatment of severe cardiac failure after cardiac operations. Am Thorac Surg 1995; 59: 523–530 [DOI] [PubMed] [Google Scholar]
  • 42. Beyersdorf F, Kirsh M, Buckberg GD, Allen BS: Warm glutamate/aspartate‐enriched blood cardioplegic solution for perioperative sudden death. J Thorac Cardiovasc Surg 1992; 104: 1141–1147 [PubMed] [Google Scholar]
  • 43. Choi DW: Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 1987; 403: 333–336 [DOI] [PubMed] [Google Scholar]
  • 44. Kochhar A, Zivin JA, Lyden PD, Mazzarella V: Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol 1988; 45: 148–153 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES